Long-term efficacy of enzyme replacement therapy for Adenosine deaminase (ADA)-deficient Severe Combined Immunodeficiency (SCID)
- 22 August 2005
- journal article
- Published by Elsevier in Clinical Immunology
- Vol. 117 (2) , 133-143
- https://doi.org/10.1016/j.clim.2005.07.006
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- Lymphocyte subsets in healthy children from birth through 18 years of ageJournal of Allergy and Clinical Immunology, 2003
- Long-term survival and transplantation of haemopoietic stem cells for immunodeficiencies: report of the European experience 1968–99The Lancet, 2003
- Correction of ADA-SCID by Stem Cell Gene Therapy Combined with Nonmyeloablative ConditioningScience, 2002
- The Use of Enzyme Therapy to Regulate the Metabolic and Phenotypic Consequences of Adenosine Deaminase Deficiency in MicePublished by Elsevier ,2000
- Gene Therapy of Human Severe Combined Immunodeficiency (SCID)-X1 DiseaseScience, 2000
- Hematopoietic Stem-Cell Transplantation for the Treatment of Severe Combined ImmunodeficiencyNew England Journal of Medicine, 1999
- T lymphocytes with a normal ADA gene accumulate after transplantation of transduced autologous umbilical cord blood CD34+ cells in ADA-deficient SCID neonatesNature Medicine, 1998
- T lymphocyte ontogeny in adenosine deaminase-deficient severe combined immune deficiency after treatment with polyethylene glycol-modified adenosine deaminase.Journal of Clinical Investigation, 1993
- Comparison of Red Cell Transfusion and Polyethylene Glycol-Modified Adenosine Deaminase Therapy in an Adenosine Deaminase-Deficient ChildPediatric Research, 1990
- Treatment of Adenosine Deaminase Deficiency with Polyethylene Glycol–Modified Adenosine DeaminaseNew England Journal of Medicine, 1987